11:19 AM EDT, 04/29/2024 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Monday that the US Food and Drug Administration has approved Libervant Buccal Film to treat intermittent, stereotypic episodes of frequent seizure activity, which are distinct from a patient's usual seizure pattern, in epileptic patients aged 2 years to 5 years old.

Aquestive Chief Executive Officer Daniel Barber said the company is already able to fill non-Medicaid prescriptions and expects to expand its distribution over the coming weeks.

In addition, the company said its Anaphylm Sublingual Film clinical development program remains on track, with a new drug application expected to be submitted by the end of the year.

Shares of Aquestive Therapeutics ( AQST ) were down nearly 15% in recent trading.

Price: 3.46, Change: -0.61, Percent Change: -14.94